ssbet77
ssbet77
Aaron Rodgers suggests a 'curse' might be the reason for the Jets' losing ways FLORHAM PARK, N.J. (AP) — The New York Jets might be dealing with an opponent even tougher to overcome than their poor play, missed opportunities and ill-timed mistakes. Dennis Waszak Jr., The Associated Press Dec 11, 2024 3:29 PM Dec 11, 2024 3:35 PM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message New York Jets quarterback Aaron Rodgers (8) gestures on the line of scrimmage during the second half of an NFL football game Miami Dolphins, Sunday, Dec. 8, 2024, in Miami Gardens, Fla. (AP Photo/Wilfredo Lee) FLORHAM PARK, N.J. (AP) — The New York Jets might be dealing with an opponent even tougher to overcome than their poor play, missed opportunities and ill-timed mistakes. Wide receiver Garrett Wilson suggested last Sunday a losing “gene” might be an explanation for the Jets’ inability to pull out victories after the team dropped to 3-10 with a loss at Miami. On Wednesday, Aaron Rodgers presented another perhaps more sinister reason. “I mean, it might be something like that," the quarterback said of Wilson's theory. "It might be some sort of curse we've got to snap as well.” Generations of frustrated Jets fans have half-jokingly insisted there have been negative forces at work against the franchise since Joe Namath delivered on his Super Bowl guarantee in January 1969. It remains the team's only appearance in the NFL's biggest game. Rodgers has been there once — and won — with Green Bay. The 41-year-old quarterback came to New York hoping to finally lead the Jets back to the Super Bowl. He even commented on how lonely the team's only Lombardi Trophy looked during his introductory news conference 20 months ago. Instead, Rodgers' first season in New York was cut short by a torn Achilles tendon just four snaps in, immediately resurrecting "curse” theories among jaded Jets fans. With its loss last Sunday, New York extended its playoff drought to 14 straight years, the longest active skid among the major North American sports leagues. And the team will be looking for a new general manager and coach after this season, and Rodgers' future in New York is very much up in the air. “Whatever the case, this team, this organization is going to figure out how to get over the hump at some point,” Rodgers said. “The culture is built by the players. There’s a framework set down by the organization, by the upper ups, by the staff. But in the end, it’s the players that make it come to life. "And at some point, everybody’s going to have to figure out what that special sauce is to turn those games that should be wins into wins.” The Jets have held the lead in the fourth quarter in five games this season. They've lost each of them, including the past three games. New York's inability to come away with wins in those prompted Wilson's “gene” theory. “I’m not exactly sure what he was talking about there,” Rodgers said with a smile. "I don’t know what the proper nomenclature is for the situation where we’ve lost some leads or haven’t been able to take the lead late in the game, but that’s the way it goes sometimes. We haven’t been great in situational football. “A lot of those games come down to the plays in the first and second, even third quarter, where if you make the play the game is not in that situation. But in those situations, we haven’t been very good on offense or defense or even (special) teams.” Rodgers said “it takes a conscious effort, it takes an intentional effort” to establish a winning culture, and it includes leadership, practice habits and setting standards inside and outside of the locker room. And this year's Jets, Rodgers said, are “on the edge” of that. “We just haven’t quite figured out how to get that special sauce worked out, mixed up,” he said. “It’s close and a lot of great guys are in the locker room. There’s some good mix of veterans and young guys, but we just haven’t quite put it all together.” ___ AP NFL: https://apnews.com/hub/NFL Dennis Waszak Jr., The Associated Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Get your daily Victoria news briefing Email Sign Up More Football (NFL) Raiders QB Aidan O'Connell back at practice, but status is undetermined for Falcons game Dec 11, 2024 4:10 PM Vince Carter, Tracy McGrady join Bills' ownership group as limited partners Dec 11, 2024 4:08 PM Chargers QB Justin Herbert does not practice because of left ankle injury Dec 11, 2024 3:59 PM
Guest Opinion: AI, blockchain, and the coming online economic boomFlavor Flav Shares Thoughts on Chappell Roan Speaking Out on Fan Interactions, Says It’s ‘One of the Biggest Mistakes’
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. “The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. “Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company’s Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company’s common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient’s condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company’s Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the Company’s ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.comDonald Trump set to be named Time's 'Person of the Year'
LOS ANGELES (AP) — Southern California quarterback Miller Moss is entering the transfer portal after losing the Trojans' starting job last month. Moss made his announcement on social media Monday. Moss started the Trojans ' bowl victory last season and their first nine games this season before coach Lincoln Riley replaced him with Jayden Maiava in early November. “Being a USC Trojan was a lifelong dream of mine,” Moss wrote. “Putting on the cardinal and gold and competing on behalf of my teammates and school is something I will forever take pride in. I poured everything I have into this — body, heart, mind and soul — and am humbled by and proud of what my teammates and I accomplished.” Moss, who was born in Los Angeles and went to high school in the San Fernando Valley, signed with USC before Riley arrived at the school. Moss also stayed with the Trojans after Caleb Williams transferred from Oklahoma to rejoin Riley, and he served as Williams’ backup for two seasons before getting his chance to play with six touchdown passes in last year's Holiday Bowl. Moss completed 64.4% of his passes this season for 2,555 yards with 18 touchdowns and nine interceptions. After a spectacular 378-yard performance to beat LSU in the Trojans' season opener, Moss didn't play poorly as a starter, but he also wasn't a difference-maker while USC stumbled to a 4-5 record. Moss threw seven interceptions in his final five starts before losing the job to Maiava. The Trojans went 1-4 in that stretch under Moss, who plays as a more traditional pocket passer while Maiava has the mobility usually favored for quarterbacks in Riley's spread offense. “Looking towards the future, I'm unwaveringly committed to becoming an even better quarterback and leader, and to achieving this at the next level,” Moss wrote. Moss has already graduated from USC, putting him in the portal as a graduate student. USC (6-6) is headed to a lower-tier bowl game again to finish this season, its third under Riley. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the proposed offering. UBS Investment Bank is acting as lead manager. A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) on March 4, 2024, and automatically became effective upon filing. This offering is being made solely by means of a prospectus. A copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at [email protected] and [email protected] ; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at [email protected] ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected] ; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at [email protected] . This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552. Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Revolution Medicines, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding completion, timing and size of the proposed public offering. Such forward-looking statements involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events, and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Revolution Medicines undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to Revolution Medicines' business in general, see the preliminary prospectus supplement related to the proposed public offering and Revolution Medicines' current and future reports filed with the SEC, including Revolution Medicines' Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. CONTACT: Revolution Medicines Investor & Media Contacts: [email protected] ; [email protected]Xavier aims to rebound from a tough week and get one more critical tune-up for a rivalry matchup when it hosts Morgan State on Tuesday night in Cincinnati. The Musketeers (7-2) were ranked No. 22 in the AP poll two weeks ago but fell out after a 25-point loss to Michigan in the Fort Myers Tip-Off tournament final on Nov. 27. Xavier then barely escaped with a 71-68 home win over South Carolina State on Dec. 1 before losing 76-72 at TCU on Thursday. Dante Maddox Jr. came off the bench to score nine points in 20 minutes on three 3-pointers against the Horned Frogs. He also grabbed six rebounds before fouling out. The Musketeers have been waiting for the Toledo transfer to add a punch to an underwhelming bench cast that many thought would be a strength for Xavier coming into the season. "I really feel like you can almost be baited into a false sense of how deep your team is because you're around guys every day and have a good, older group, which we do," Musketeers coach Sean Miller said. "You see the good in a lot of different guys. It's not until you get 8 to 10, 10 to 15 games in when you truly understand how deep your team is." Maddox hit a 3-pointer and started a fastbreak with a steal that gave Xavier a 60-54 lead with 7:28 remaining, but the Musketeers faded down the stretch and lost for the second time in three games. Maddox is averaging 4.7 points per game, while Ryan Conwell leads the team with 16.6. Tuesday's game will be the last chance for Xavier to straighten up before visiting No. 22 Cincinnati on Saturday for the teams' annual intense crosstown showdown. Morgan State (5-7) is coming off a 102-81 road loss at Bowling Green on Saturday. Preseason All-MEAC First Team selection Will Thomas led the Bears with 19 points on 8-of-15 shooting from the field, while Kameron Hobbs scored 12 points off the bench. Amahrie Simpkins made all five of his field-goal attempts to add 11 points and Wynston Tabbs had 10 points, six rebounds and six assists. Tabbs leads Morgan State in scoring this season at 16.8 points per game, while Simpkins (12.8) and Thomas (12.2) round out the Bears' double-digit scorers. The Bears have struggled away from home, losing all five road contests this season. --Field Level MediaAs U.S. goalkeeper Alyssa Naeher looked ahead to the next Women's World Cup in 2027, she calculated what that would look like at her age. Read this article for free: Already have an account? To continue reading, please subscribe: * As U.S. goalkeeper Alyssa Naeher looked ahead to the next Women's World Cup in 2027, she calculated what that would look like at her age. Read unlimited articles for free today: Already have an account? As U.S. goalkeeper Alyssa Naeher looked ahead to the next Women’s World Cup in 2027, she calculated what that would look like at her age. Now 36, she already has a World Cup title and won an Olympic gold medal this year in France. She considered the mental, physical and emotional toll of a new cycle and decided it was time to step away. “Honestly, I think I’ve been somebody that has given everything I’ve had to this team. I don’t do anything halfway. It’s kind of, if you can give 100% to it, then keep going,” she said. “With that in mind, I kind of just felt like this was the right time coming off of the Olympics, having the year that we had, entering into a new cycle, a new stage for this team.” Naeher is the latest veteran to announce she’s stepping down from the national team as the next generation takes over under coach Emma Hayes. Among those who have wrapped up their soccer careers in the past couple of years include World Cup winners Megan Rapinoe, Alex Morgan, Kelley O’Hara and Ali Krieger. Naeher will be with the team for two more matches in the coming week. The Americans play England at Wembley Stadium on Saturday and then the Netherlands in The Hague on Tuesday. Naeher said she’s excited about the next generation of goalkeepers. In addition to Naeher, Mandy Haught of the Utah Royals and Phallon Tullis-Joyce of Manchester United are on the roster for the upcoming matches. Other goalkeepers who have been on recent rosters include Casey Murphy and Jane Campbell. “I think the beauty of goalkeeping is that it’s not really a one-size-fits-all kind of position,” she said. “The more that you can understand — that’s going to be the challenge any young goalkeeper coming up, is really taking the time to understand what your strengths are and make them really, really elite and separate yourself.” Naeher spoke on Wednesday from London after announcing her retirement on social media Monday. Naeher made her senior debut with the national team in 2014 and was a backup to Hope Solo at the 2015 World Cup, which the United States won. She became the team’s regular starter following the 2016 Rio de Janeiro Olympics and was on the squad that repeated as World Cup winners in 2019. Naeher won a bronze medal at the Tokyo Olympics in 2021 before the U.S. earned gold this year in Paris. She made a key one-handed save in stoppage time to preserve the Americans’ 1-0 victory over Brazil in the Olympic final. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. For her career, Naeher has appeared 113 games with 110 starts, 88 wins and 68 shutouts. She had four shutouts over the course of the Olympic tournament in France. While she’s leaving the national team, she’ll play one more year for her club team, the Chicago Red Stars in the National Women’s Soccer League. “I hope that I can be remembered as a good teammate, as a competitor, as somebody that was looked on as someone that could be relied upon on the field and supported those players around me,” she said. “I think it’s just been a really special team to be a part of. And I’m very proud of what we have been able to accomplish over the years.” ___ AP soccer: https://apnews.com/hub/soccer Advertisement Advertisement
SAN JUAN, Puerto Rico (AP) — Colin Smalls scored 23 points as American held off the University of Albany 81-77 at the Puerto Rico Classico tournament on Sunday. Smalls went 8 of 11 from the field (5 for 7 from 3-point range) for the Eagles (3-4). Elijah Stephens scored 20 points while shooting 7 of 10 from the field and 6 for 9 from the line and added five rebounds and six assists. Matt Mayock shot 6 for 8, including 3 for 4 from beyond the arc to finish with 17 points. Justin Neely led the Great Danes (5-2) in scoring, finishing with 20 points and seven rebounds. Byron Joshua added 17 points and six rebounds for Albany (NY). Kheni Briggs also recorded 14 points. The Great Danes ended a five-game winning streak with the loss. American went into halftime ahead of Albany (NY) 39-30. Smalls put up 12 points in the half. American used an 8-0 run in the second half to build a 19-point lead at 65-46 with 10:27 left in the half before finishing off the win. NEXT UP American plays Saturday against UPR-Mayaguez, and Albany (NY) visits Georgetown on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
- Previous:
- Next: #ssbet77
